Industri

Alkermes’ alixorexton secures FDA and EC orphan designa...

The FDA granted the status to alixorexton for idiopathic hypersomnia while the E...

ILAMED expands international presence with centres in K...

Institute to launch Cairo centre in September 2026 as part of its overseas exp...

Security System

SentriZone® by Crotega is a facility-based security system designed to help orga...

ChristianaCare Opens Neighborhood Hospital in Aston, Pa.

ChristianaCare opened the $50.9 million ChristianaCare Hospital, Aston, in early...

Ensera and Argonaut partner to streamline supply for dr...

Delivering an integrated fill-finish and device assembly and packing collaborati...

Simcere and Stanford partner to develop IPF therapies

Under the deal, Simcere will provide funding for exploratory research on a first...

FDA clears MSD’s Keytruda combo plus Welireg for ccRCC ...

This approval covers patients with ccRCC who are at intermediate-high or high ri...

Novartis India launches Pluvicto for PSMA-positive meta...

Radioligand therapy approved for eligible patients with PSMA-positive prostate ...

Ipca Laboratories and Bhami’s Research Laboratory signs...

Agreement enables development and commercialisation of monoclonal antibody prod...

Alembic receives USFDA final approval for Tretinoin Cre...

ANDA approved for Tretinoin Cream USP, 0.05%, referencing Retin-A Cream, 0.05% ...

ISO 20417:2026 and the Introduction of "Applicable Poli...

The publication of ISO 20417:2026, Medical Devices — Information to be Supplied ...

Canopy LED Fixture

The Ace LED Canopy (AC2) by Linmore is made to last with its rugged aluminum die...

Jack Reed Joins NexCore Group as Vice President of Desi...

Jack Reed, AIA, recently joined the healthcare real estate development firm NexC...

Why ingredient transparency matters more than ever in c...

Dr Aishwarya Pandit highlights why ingredient transparency has become essential...

CDSCO’s cosmetic regulations: The rules exist. The enfo...

People have died in India’s aesthetic clinics. Not in rare surgical catastrophe...

China’s NMPA approves Akeso’s gumokimab for plaque psor...

The approval is based on data from one pivotal Phase III trial (AK111-301) and t...